BioSpace News Archive

According to the report, the global stem cells market was valued at US$ 11.73 Bn in 2020 and is projected to expand at a CAGR of 10.4% from 2021 to 2028.

Fact.MR, a Market Research and Competitive Intelligence Provider - Fact.MR, a market research and competitive intelligence provider, has conducted a comprehensive analysis on the global spectrometry market, which is expected to rise at a CAGR of 6.4% over the forecast period.

Wilmington, Delaware, United States: According to the report, the global medical imaging equipment market was valued at US$ 30.7 Bn in 2020 and is projected to expand at a CAGR of 5.4% from 2021 to 2028.

Wilmington, Delaware, United States: According to the report, the global medical education market was valued at ~US$ 32 Bn in 2019 and is projected to expand at a CAGR of ~5% from 2020 to 2030.

Palette Life Sciences announced U.S. Food and Drug Administration 510 clearance of Barrigel®, the first and only hyaluronic acid rectal spacer that separates the prostate from the rectum to protect it during radiation therapy treatment for prostate cancer.

SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that management will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference.

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced the company has entered into an exclusive collaboration with Pint Pharma GmbH to register and promote ORLADEYO® (berotralstat) in the pan-Latin America (LATAM) region.

Satsuma Pharmaceuticals, Inc. announced that five abstracts highlighting STS101 and its differentiated features were selected for presentation at the American Headache Society’s 64th Annual Scientific Meeting.

Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), today announced updates on its Phase 1 clinical trial evaluating FPI-1434 as a monotherapy for the treatment of solid tumors expressing IGF-1R and its Phase 1 clinical trial evaluating FPI-1966 for the treatment of solid tumors expressing FGFR3.

Existing investor syndicate supports atrial shunting as effective therapy for heart failure patients.